$692.03▲ 5.67 (0.83%)
Real-time prices · US MarketsQ·Score
Buy
8 / 10
Clean balance sheet with low leverage (0.1× debt-to-equity).
Quality
8.2
Health
9.7
Growth
7.3
Valuation
7.2
Sentiment
7.7
Analyst Target
$877.73
▲ +26.8% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
16.9×
price-to-earnings
Forward P/E
13.1×
next 12 months est.
Market Cap
$72.6B
market capitalization
Div Yield
0.55%
dividend yield
Profit Margin
29.6%
net profit margin
Gross Margin
44.6%
revenue minus COGS
ROE
14.5%
return on equity
Beta
0.40
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$476 — $821
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is REGN a good stock to buy right now?
Based on our Q·Score of 8/10, Regeneron Pharmaceuticals, Inc. is rated "Buy". Clean balance sheet with low leverage (0.1× debt-to-equity). This analysis is based on fundamentals, analyst consensus, and valuation data, and should not be considered financial advice.
What is the analyst price target for REGN?
The consensus price target for REGN is $877.73, based on the recommendations of 28 Wall Street analysts. This implies 26.8% upside from the current price of $692.03.
Is REGN overvalued or undervalued?
Regeneron Pharmaceuticals, Inc. (REGN) appears reasonably valued or undervalued relative to analyst targets and sector peers. It trades at a 13.1× forward P/E ratio. Analysts see 27% upside to their $877.73 consensus target.
When does Regeneron Pharmaceuticals, Inc. report its next earnings?
Regeneron Pharmaceuticals, Inc.'s next earnings report is expected on approximately July 30, 2026.
What is Regeneron Pharmaceuticals, Inc.'s profit margin?
Regeneron Pharmaceuticals, Inc. has a net profit margin of 29.6%, which is considered high and reflects strong pricing power. Its gross margin stands at 44.6%, reflecting a more cost-intensive business model.
What is REGN's dividend yield?
Regeneron Pharmaceuticals, Inc. currently offers a dividend yield of 0.55%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.
Is Regeneron Pharmaceuticals, Inc.'s revenue growing?
Regeneron Pharmaceuticals, Inc. is reporting solid revenue growth of 19.0% year-over-year. However, earnings declined 7.2%, which warrants monitoring.
How much debt does Regeneron Pharmaceuticals, Inc. have?
Regeneron Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.09×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 4.66×, indicating comfortable short-term liquidity.